Institutional shares held 53.9 Million
122K calls
239K puts
Total value of holdings $8.78B
$19.9M calls
$39M puts
Market Cap $8.29B
50,863,300 Shares Out.
Institutional ownership 105.94%
# of Institutions 708


Latest Institutional Activity in CRL

Top Purchases

Q4 2024
D1 Capital Partners L.P. Shares Held: 936K ($153M)
Q4 2024
Impactive Capital LP Shares Held: 1.2M ($196M)
Q4 2024
Norges Bank Shares Held: 536K ($87.3M)
Q4 2024
Millennium Management LLC Shares Held: 372K ($60.7M)
Q4 2024
Wellington Management Group LLP Shares Held: 4.08M ($665M)

Top Sells

Q4 2024
Congress Asset Management CO Shares Held: 4.36K ($711K)
Q4 2024
Eminence Capital, LP Shares Held: 627K ($102M)
Q4 2024
Thrivent Financial For Lutherans Shares Held: 5.42K ($884K)
Q4 2024
Clearbridge Investments, LLC Shares Held: 775K ($126M)
Q4 2024
Marshall Wace, LLP Shares Held: 21.6K ($3.52M)

About CRL

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.


Insider Transactions at CRL

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
61.6K Shares
From 19 Insiders
Grant, award, or other acquisition 54K shares
Open market or private purchase 7.59K shares
Sell / Disposition
82.7K Shares
From 20 Insiders
Payment of exercise price or tax liability 17.2K shares
Bona fide gift 12.7K shares
Open market or private sale 52.8K shares

Track Institutional and Insider Activities on CRL

Follow CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRL shares.

Notify only if

Insider Trading

Get notified when an Charles River Laboratories International, Inc. insider buys or sells CRL shares.

Notify only if

News

Receive news related to CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Track Activities on CRL